<DOC>
	<DOC>NCT01353859</DOC>
	<brief_summary>This multicenter, open-label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in combination with methotrexate in patients with active rheumatoid arthritis who have an inadequate response to non-biologic disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks for a total of 6 infusions plus methotrexate 10-25 mg orally weekly. Anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Moderate to severe active rheumatoid arthritis (RA) of &gt;/= 6 months duration Prior treatment with DMARDs for &gt;/= 12 weeks (at stable dose for &gt;/= 8 weeks) Inadequate clinical response to stable dose of nonbiologic DMARD (either single or in combination) Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following enrollment Autoimmune disease other than RA History of or current inflammatory joint disease other than RA Previous treatment with any biologic drug that is used in the treatment of RA Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline Impaired liver, renal or hematologic function Active current or history of recurrent infection History of or currently active primary or secondary immunodeficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>